**2020 surveillance –** [**Urinary tract infection in under 16s: diagnosis and management (CG54)**](https://www.nice.org.uk/guidance/cg54)

**Stakeholder consultation comments form - proposal ‘yes to update’**

Consultation on the proposal ‘to update’opens at: 9am on Monday, 20 July 2020

Comments on proposal to be submitted: no later than 5pm on Friday, 31 July 2020

|  |
| --- |
| **Please enter the name of your registered stakeholder or respondent organisation below.**Please use this form for submitting your comments to NICE. 1. Please put each new comment in a new row.
2. Please note – we cannot accept comments forms with attachments such as research articles, letters or leaflets. If we receive forms with attachments we will return them without reading the comments. If you resubmit the comments on a form without attachments, this must be by the consultation deadline.
3. If you wish to draw our attention to published studies, please supply the full reference.
4. If you’re commenting for an organisation, your organisation needs to be [registered as a stakeholder](https://www.nice.org.uk/get-involved/stakeholder-registration).

Not eligible? Contact the [registered stakeholder organisation](https://www.nice.org.uk/guidance/cg54/update/cg54-update-1/documents/stakeholder-list) that most closely represents your interests and pass your comments to them.We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation. |
| Organisation name – Stakeholder or respondent (if you are commenting as an individual rather than a registered stakeholder or respondent organisation, please leave blank): |  |
| DisclosurePlease disclose whether the organisation has any past or current, direct or indirect links to, or receives funding from, the tobacco industry. |  |
| Name of commentator: |  |

[Developing NICE guidelines: the manual](https://www.nice.org.uk/process/pmg20/chapter/1-introduction-and-overview) gives an overview of the processes used in surveillance reviews of NICE clinical guidelines.

| **ID** | **Questions**  | **Overall response**yes / no | **Comments**Please insert each new comment in a new row |
| --- | --- | --- | --- |
| 1 | Do you agree with the proposal to update the guideline? |  |  |
| 2 | Do you have any comments on areas excluded from the scope of the guideline? |  |  |
| 3 | Do you have any comments on equalities issues? |  |  |
| 4 | Would contrast-enhanced voiding urosonography (ceVUS) be considered a suitable alternative to micturating cystourethrogram (MCUG) for detecting and evaluating vesicoureteric reflux (VUR) in children? What are the practical considerations, and how widespread is the use of ceVUS in the NHS? Please provide any relevant supporting evidence. |  |  |
| 5 | NICE acknowledges that services may be affected by the current COVID-19 situation, however most of the content of the guideline was developed before this arose. Please tell us if there are any particular issues we should be considering? |  |  |

**Please email this form to:** **surveillance@nice.org.uk**

**Closing date: 31 July 2020**

**PLEASE NOTE:**

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, if NICE’s reasonable opinion is that the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.